News

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...
Revelation Biosciences, Inc. (NASDAQ:REVB), a clinical-stage life sciences company dedicated to rebalancing inflammation for ...
Castle Biosciences, Inc. (NASDAQ:CSTL) has announced new data to be presented at ASCO 2025 showing that its ...
The Holliston, Massachusetts-based company said it had a loss of $1.14 per share. Losses, adjusted for one-time gains and costs, were 1 cent per share. While Harvard Bioscience, Inc. ( NASDAQ ...
Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in ...
Colossal Biosciences is a trailblazing company that's pushing the boundaries of genetic engineering and shattering them.
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...
The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.